BTOG 2019 | DDR proteins emerging as biomarkers and targets in lung cancer: the case of hSSB1

Kenneth O'Byrne

Presenting an array of work from his group in Brisbane on DNA damage repair proteins that are emerging as biomarkers and targets in lung cancer, Ken O’Byrne, MD, of the Princess Alexandra Hospital, Brisbane, Queensland, Australia, spoke to us about the context and application of this research. Prof. O’Byrne highlights hSSB1, discovered by his research partner Prof. Derek Richard, a highly conserved and important protein in the DNA damage repair process, and goes on to discuss the upcoming translation of this work into a clinical trial. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.

Share this video  
Similar topics
Related videos
3:07
Neoadjuvant atezolizumab in NSCLC
David Kwiatkowski
0:42
Key challanges in NSCLC
David Kwiatkowski
0:55
TTFields as an anti-mitotic therapy
Ori Farber
0:48
The LUNAR study: TTFields for treating NSCLC
Ori Farber
2:03
The STELLAR study: TTFields for malignant pleural mesothelioma
Ori Farber
Lung Cancer
BTOG 2019
Interview
25th January 2019
More from Kenneth O'Byrne
The key unanswered question in lung cancer?
The evolution of BTOG and thoracic oncology care in the UK
Translational research: targeting cancer genetics and dependencies
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals